Literature DB >> 33044746

Microglia/macrophages express alternative proangiogenic factors depending on granulocyte content in human glioblastoma.

Anne Blank1, Irina Kremenetskaia1, Ruth M Urbantat1, Güliz Acker1,2,3, Kati Turkowski1, Josefine Radke3,4,5, Ulf C Schneider2, Peter Vajkoczy1,2, Susan Brandenburg1.   

Abstract

Myeloid cells are an inherent part of the microenvironment of glioblastoma multiforme (GBM). There is growing evidence for their participation in mechanisms of tumor escape, especially in the development of resistance following initially promising anti-VEGF/VEGFR treatment. Thus, we sought to define the capability of myeloid cells to contribute to the expression of proangiogenic molecules in human GBM. We investigated GBM specimens in comparison with anaplastic astrocytoma (WHO grade III) and epilepsy patient samples freshly obtained from surgery. Flow cytometric analyses revealed two distinct CD11b+ CD45+ cell populations in GBM tissues, which were identified as microglia/macrophages and granulocytes. Due to varied granulocyte influx, GBM samples were subdivided into groups with low (GBM-lPMNL) and high (GBM-hPMNL) numbers of granulocytes (polymorphonuclear leukocytes; PMNL), which were related to activation of the microglia/macrophage population. Microglia/macrophages of the GBM-lPMNL group were similar to those of astrocytoma specimens, but those of GBM-hPMNL tissues revealed an altered phenotype by expressing high levels of CD163, TIE2, HIF1α, VEGF, CXCL2 and CD13. Although microglia/macrophages represented the main source of alternative proangiogenic factors, additionally granulocytes participated by production of IL8 and CD13. Moreover, microglia/macrophages of the GBM-hPMNL specimens were highly associated with tumor blood vessels, accompanied by remodeling of the vascular structure. Our data emphasize that tumor-infiltrating myeloid cells might play a crucial role for limited efficacy of anti-angiogenic therapy bypassing VEGF-mediated pathways through expression of alternative proangiogenic factors.
© 2020 The Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd. © 2020 The Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.

Entities:  

Keywords:  CD45; CSF; CXCL2; GBM; granulocytes; macrophages; microglia; tumor angiogenesis; tumor microenvironment

Mesh:

Substances:

Year:  2020        PMID: 33044746     DOI: 10.1002/path.5569

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  10 in total

Review 1.  Signal Pathways Involved in the Interaction Between Tumor-Associated Macrophages/TAMs and Glioblastoma Cells.

Authors:  Xiaojin Liu; Yuan Liu; Yiwei Qi; Yimin Huang; Feng Hu; Fangyong Dong; Kai Shu; Ting Lei
Journal:  Front Oncol       Date:  2022-05-04       Impact factor: 5.738

2.  The molecular feature of macrophages in tumor immune microenvironment of glioma patients.

Authors:  Hao Zhang; Yue-Bei Luo; Wantao Wu; Liyang Zhang; Zeyu Wang; Ziyu Dai; Songshan Feng; Hui Cao; Quan Cheng; Zhixiong Liu
Journal:  Comput Struct Biotechnol J       Date:  2021-08-14       Impact factor: 7.271

3.  Implications of a granulocyte-high glioblastoma microenvironment in immune suppression and therapy resistance.

Authors:  Shanmugarajan Krishnan; Zohreh Amoozgar; Dai Fukumura; Rakesh K Jain
Journal:  J Pathol       Date:  2021-03-23       Impact factor: 7.996

Review 4.  Distinction of Microglia and Macrophages in Glioblastoma: Close Relatives, Different Tasks?

Authors:  Susan Brandenburg; Anne Blank; Alexander D Bungert; Peter Vajkoczy
Journal:  Int J Mol Sci       Date:  2020-12-27       Impact factor: 5.923

Review 5.  Interactions Between Anti-Angiogenic Therapy and Immunotherapy in Glioblastoma.

Authors:  Saket Jain; Eric J Chalif; Manish K Aghi
Journal:  Front Oncol       Date:  2022-01-12       Impact factor: 6.244

6.  Tumor-Associated Microglia/Macrophages as a Predictor for Survival in Glioblastoma and Temozolomide-Induced Changes in CXCR2 Signaling with New Resistance Overcoming Strategy by Combination Therapy.

Authors:  Ruth M Urbantat; Claudius Jelgersma; Susan Brandenburg; Melina Nieminen-Kelhä; Irina Kremenetskaia; Julia Zollfrank; Susanne Mueller; Kerstin Rubarth; Arend Koch; Peter Vajkoczy; Gueliz Acker
Journal:  Int J Mol Sci       Date:  2021-10-16       Impact factor: 5.923

7.  Combining TMZ and SB225002 induces changes of CXCR2 and VEGFR signalling in primary human endothelial cells in vitro.

Authors:  Susan Brandenburg; Gueliz Acker; Ruth M Urbantat; Claudius Jelgersma; Peter Vajkoczy
Journal:  Oncol Rep       Date:  2022-07-20       Impact factor: 4.136

Review 8.  Macrophages/Microglia in the Glioblastoma Tumor Microenvironment.

Authors:  Jun Ma; Clark C Chen; Ming Li
Journal:  Int J Mol Sci       Date:  2021-05-28       Impact factor: 5.923

9.  The CXCL2/IL8/CXCR2 Pathway Is Relevant for Brain Tumor Malignancy and Endothelial Cell Function.

Authors:  Ruth M Urbantat; Anne Blank; Irina Kremenetskaia; Peter Vajkoczy; Güliz Acker; Susan Brandenburg
Journal:  Int J Mol Sci       Date:  2021-03-05       Impact factor: 5.923

Review 10.  Therapeutic Potential of Selenium in Glioblastoma.

Authors:  Eduard Yakubov; Thomas Eibl; Alexander Hammer; Markus Holtmannspötter; Nicolai Savaskan; Hans-Herbert Steiner
Journal:  Front Neurosci       Date:  2021-05-28       Impact factor: 5.152

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.